Veru (NASDAQ:VERU) Lowered to “Sell” Rating by Wall Street Zen

Veru (NASDAQ:VERU) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

A number of other brokerages have also commented on VERU. Weiss Ratings reissued a “sell (e+)” rating on shares of Veru in a report on Wednesday, January 21st. Canaccord Genuity Group started coverage on shares of Veru in a research note on Thursday, December 18th. They set a “buy” rating and a $25.00 price target on the stock. Finally, Oppenheimer reissued an “outperform” rating on shares of Veru in a report on Thursday, December 18th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $22.50.

Veru Price Performance

NASDAQ VERU opened at $2.53 on Friday. The stock’s 50 day simple moving average is $2.43 and its 200 day simple moving average is $3.31. Veru has a one year low of $2.10 and a one year high of $7.40. The firm has a market cap of $40.61 million, a PE ratio of -1.15 and a beta of -1.42.

Veru (NASDAQ:VERU) last posted its quarterly earnings data on Wednesday, December 17th. The company reported ($0.31) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.18. During the same period last year, the business posted ($0.28) earnings per share. As a group, equities analysts expect that Veru will post -0.22 earnings per share for the current year.

Institutional Trading of Veru

Institutional investors have recently bought and sold shares of the business. Blair William & Co. IL lifted its stake in shares of Veru by 8.6% in the 2nd quarter. Blair William & Co. IL now owns 380,000 shares of the company’s stock valued at $221,000 after purchasing an additional 30,000 shares during the period. 180 Wealth Advisors LLC grew its stake in shares of Veru by 5.9% during the second quarter. 180 Wealth Advisors LLC now owns 458,887 shares of the company’s stock worth $267,000 after purchasing an additional 25,554 shares during the period. Y Intercept Hong Kong Ltd bought a new stake in Veru in the second quarter valued at about $90,000. Atria Investments Inc lifted its stake in Veru by 11.5% in the second quarter. Atria Investments Inc now owns 282,281 shares of the company’s stock valued at $164,000 after buying an additional 29,025 shares during the period. Finally, Allworth Financial LP acquired a new position in Veru in the second quarter valued at about $45,000. Institutional investors and hedge funds own 47.16% of the company’s stock.

About Veru

Veru Inc is a clinical-stage biopharmaceutical company headquartered in Miami, Florida. The company is dedicated to the development and commercialization of novel therapies in the fields of oncology and infectious disease. Veru’s research strategy centers on advancing small-molecule and biologic candidates through clinical trials, leveraging its in-house manufacturing and formulation capabilities as well as strategic partnerships to support late-stage development.

The company’s lead product candidate is sabizabulin (VERU-111), an oral, microtubule-disrupting agent undergoing pivotal trials for indications that include metastatic castration-resistant prostate cancer and hospitalized patients with severe COVID-19.